Efficacy and Safety Study of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions

NCT00512356 | Completed Phase 2 DMC

• 1 other identifier: 549902
• Study Type: interventional
• Target: 46
• Locations: 3 countries
• Sites: 7

Brief Summary

The objective of this study was to evaluate the efficacy of the Anti-Adhesion Product (AAP) in preventing or reducing post-operative adhesion formation and re-formation in a subject population having abdominal surgery and being left with a rectal stump and a temporary stoma from a first procedure and scheduled for a laparoscopy/ laparotomy as a second procedure in the normal treatment of the subjects' disease. In both study groups, surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. In the investigational product group, AAP was applied to the rectal stump and the incision line while no specific additional treatment was applied in the control group. The surgeon assessed preexisting adhesions during the first surgery. Newly developed and re-formed adhesions were evaluated during the second surgery by a surgeon or assistant who did not know the result of randomization. The safety of the study drug was also monitored.

Conditions

Intraperitoneal Adhesions

Outcome Measures

Primary Outcomes (1)

• Incidence of adhesions around the rectal stump and/or incision line

Secondary Outcomes (6)

• Number of subjects with no adhesions

• Extent and severity of adhesions around the rectal stump

• Extent and severity of adhesions at the incision line

• Incidence, extent and severity of adhesions at sites other than the rectal stump and incision line

• Time to reach and free the rectal stump

Study Arms (2)

Investigational product group

EXPERIMENTAL

Anti-Adhesion Product was applied to the rectal stump and the incision line. Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves.

Biological: Anti-Adhesion Product

Control group

NO INTERVENTION

Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.

Interventions

Anti-Adhesion Product BIOLOGICAL

Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.

Investigational product group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent obtained from the subject or the subject's legally authorized representative prior to study entry
• Male or female subjects \> 18 years of age
• Subjects undergoing abdominal surgery with the possibility that a rectal stump would remain due to one or more of the following reasons: inflammatory bowel diseases, neoplasm, colon diverticulitis, colonic obstruction, colon polyposis, peritoneal trauma, fistula, incontinence, or other reasons
• Subjects for whom a second abdominal surgery is planned within approximately eight months of the first surgical procedure.

You may not qualify if:

• Pre operative:
• Pregnancy and lactation period
• Subjects concurrently participating in another clinical trial with a drug or a device
• Subjects who have participated in a clinical trial with a drug or a device within 30 days prior to this study
• Subjects who have had abdominal/pelvic surgery within six months prior to this study
• Subjects who have received or will receive (approximately within the next eight months) abdominal/pelvic irradiation
• Intra operative:
• Subjects with peritonitis
• Subjects with gastrointestinal metastatic cancer, or cancer growing per continuitatem into surrounding tissues
• Subjects treated with hemostatic agents (e.g. fibrin sealant, collagen, oxidized cellulose) during the first surgery
• Subjects treated with adhesion prevention agents other than the Anti-Adhesion Product (AAP) (e.g. Intergel® Adhesion Prevention Solution, Seprafilm® Membrane) during the first surgery
• Subjects with major fecal contamination needing an abdominal lavage during the first surgery

Sponsors & Collaborators

• Baxter Healthcare Corporation: lead

Study Sites (7)

Copenhagen University Hospital, Rigshospitalet Department of Gastroenterologic Surgery

Copenhagen, 2120, Denmark

Location

Odense University Hospital, Surgical Gastroenterology Department

Odense, 5000, Denmark

Location

Klinika Chirurgii Ogolnej Onkologicznej i Klatiki Piersiowej CSK WAM

Warsaw, 00 909, Poland

Location

Im. Marii Sklodowskiej-Curie, Centrum Onkologii-Instytut

Warsaw, 02 781, Poland

Location

Göteborg University, Department of Surgery, Colorectal Unit

Gothenburg, 416 85, Sweden

Location

Söder Sjukhuset, Department of Surgery

Stockholm, 118 83, Sweden

Location

Uddevalla Sjukhus, Kirurg Kliniken

Uddevalla, 451 80, Sweden

Location

Study Officials

• Baxter BioScience Investigator, MD

  Baxter Healthcare Corporation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: August 6, 2007
• First Posted: August 7, 2007
• Study Start: December 1, 2000
• Primary Completion: February 25, 2003
• Study Completion: April 1, 2003
• Last Updated: August 4, 2017

Record last verified: 2017-08

Locations

DK (2); SE (3); PL (2)